EP Patent

EP2915814A3 — Crystalline salts of sitagliptin

Assigned to Ratiopharm GmbH · Expires 2015-10-07 · 11y expired

What this patent protects

The present invention relates to crystalline monobasic, dibasic and tribasic acid addition salts of the dipeptidyl peptidase-IV inhibitor sitagliptin.

USPTO Abstract

The present invention relates to crystalline monobasic, dibasic and tribasic acid addition salts of the dipeptidyl peptidase-IV inhibitor sitagliptin.

Drugs covered by this patent

Patent Metadata

Patent number
EP2915814A3
Jurisdiction
EP
Classification
—
Expires
2015-10-07
Drug substance claim
No
Drug product claim
No
Assignee
Ratiopharm GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.